Congenital bilateral absence of vas deferens, often shortened to CBAVD, is a condition present from birth in which both vas deferens tubes do not develop normally. These two tubes normally carry sperm from the epididymis toward the urethra. In CBAVD, the testes often still make sperm, but the sperm cannot travel out in the usual way. Because of that, many men with this condition learn about it only during an infertility check. CBAVD is a recognized cause of obstructive azoospermia, which means sperm production may continue, but sperm cannot enter the semen normally. It is also strongly linked with CFTR-related disease and sometimes with mild or atypical cystic fibrosis features.
Congenital bilateral absence of vas deferens, often called CBAVD, is a birth condition in which both vas deferens tubes do not form normally. These tubes usually carry sperm from the epididymis toward the urethra. In many men with CBAVD, the testes still make sperm, erections are usually normal, and sexual desire is usually normal, but sperm cannot travel into the semen, so natural pregnancy usually does not happen. CBAVD is strongly linked with changes in the CFTR gene and is often considered part of the cystic fibrosis spectrum, although some men have only infertility and no major lung disease. The main evidence-based treatment is not a pill that rebuilds the missing tubes; it is careful diagnosis, genetic counseling, sperm retrieval, and assisted reproduction such as IVF with ICSI. 1 2 3
CBAVD is important because it is a structural cause of obstructive azoospermia, which means sperm production may be present but sperm are blocked from reaching the ejaculate. Many men learn about it only during infertility testing after a semen analysis shows azoospermia and low semen volume. Because CFTR-related disease may affect the lungs, pancreas, and future children, the evaluation should go beyond fertility alone. A man with CBAVD and his partner usually need genetic counseling and carrier testing before pregnancy attempts so they can understand the chance of passing CFTR-related disease to a child. 3 4 5
In very simple words, the body makes sperm, but the main “transport tubes” are missing on both sides. So semen may come out, but it may contain no sperm, or very few sperm if there is an unusual partial pathway. Sexual desire, erection, and masculine appearance are usually normal, because this condition mainly affects the sperm pathway rather than testosterone function. Some men also have related changes in the seminal vesicles, kidneys, or the CFTR gene pathway, so doctors often check beyond the genital tract as well.
Another names
CBAVD is also called congenital bilateral absence of the ductus deferens, congenital bilateral aplasia of the vas deferens, bilateral congenital absence of vas deferens, and sometimes male infertility due to obstructive azoospermia from absent vas deferens. In some genetics discussions, it is also described as a CFTR-related disorder when a CFTR mutation is involved. These names point to the same main problem: both sperm-carrying ducts are absent or fail to develop correctly.
Types
1) Isolated CBAVD. This type means the man has bilateral absence of the vas deferens mainly as a reproductive problem, without the full classic picture of cystic fibrosis. It is still often linked to CFTR or other gene changes, but the person may not have major lung or digestive disease.
2) CBAVD as a mild or atypical cystic fibrosis form. In this type, CBAVD is part of the wider CFTR-related disease spectrum. The person may have mild sinus, lung, or digestive symptoms, even if he does not meet the full classic definition of cystic fibrosis.
3) CBAVD with associated urogenital anomalies. In some men, CBAVD occurs together with abnormalities such as absent or small seminal vesicles, or kidney abnormalities like unilateral renal agenesis. This type reminds doctors to look at the whole urinary and reproductive tract, not only fertility.
4) Complete congenital absence of the vas deferens. In complete forms, the duct is absent along its expected course. This usually gives a stronger obstruction picture and is the classic pattern seen in CBAVD.
5) Partial or segmental developmental defect. Some reviews of congenital absence of vas deferens describe partial aplasia or incomplete development as a related form in the same disease family. This is less classic than true bilateral complete absence, but it is part of the developmental spectrum doctors discuss.
Causes
This section is written honestly: medicine does not prove 20 common direct causes for CBAVD in the same way it proves 20 causes for fever or pain. The best evidence supports a smaller number of main genetic and developmental causes, while many cases remain unexplained. So below I list the main proven causes, strong genetic contributors, and well-described developmental mechanisms or associations.
1) CFTR gene mutations. This is the most important and best-known cause. More than half of affected men have CFTR mutations, and in many people CBAVD is considered part of the CFTR-related disease spectrum.
2) Mild CFTR variants with residual function. Some men carry milder CFTR changes that do not cause classic cystic fibrosis but still disturb development of the vas deferens. These variants allow some CFTR function to remain, so the disease may stay limited mainly to fertility.
3) One mild plus one severe CFTR variant. A man may inherit one milder CFTR mutation and one more severe cystic-fibrosis-causing mutation. This combination can produce CBAVD without the full lung and pancreas picture of classic cystic fibrosis.
4) CFTR 5T-related splicing abnormality. A well-known CFTR intron 8 variant called the 5T allele can reduce correct gene splicing and lower normal CFTR protein formation. This variant is often discussed in CBAVD genetics.
5) TG repeat and 5T interaction in CFTR. The effect of the 5T allele may become stronger when certain adjacent TG repeat patterns are present. This can further weaken normal CFTR processing and increase the risk of CBAVD.
6) ADGRG2 mutation. ADGRG2 is the second most important gene linked to CBAVD, especially in cases without CFTR mutations. Because it is X-linked, its inheritance pattern differs from the common CFTR pathway.
7) X-linked ADGRG2-related disease. In some men, the deeper cause is not just “an ADGRG2 mutation” but an X-linked developmental disorder of the male genital tract caused by this gene. Clinically, it can look very similar to CFTR-related CBAVD.
8) Embryologic mesonephric duct maldevelopment. The vas deferens develops from the mesonephric or Wolffian duct. If this developmental pathway fails early in fetal life, the vas deferens may not form properly on both sides.
9) Abnormal fetal development of the Wolffian duct derivatives. CBAVD belongs to a group of developmental defects affecting structures that come from the Wolffian duct, including the epididymis, seminal vesicle, and vas deferens. This explains why associated genital tract anomalies may coexist.
10) Defective chloride and water transport in the genital tract. CFTR normally helps move chloride and water across cells. When this process is disturbed during fetal development, the environment inside the developing genital tract becomes abnormal and may damage or prevent normal duct formation.
11) Thick and sticky secretions during development. MedlinePlus explains that abnormal mucus can clog the vas deferens as they form, leading them to degenerate before birth. This is a key mechanism in CFTR-related CBAVD.
12) Atypical cystic fibrosis. Some men do not have classic cystic fibrosis but do have a milder CFTR-related disease state. In those men, CBAVD may be the main or only obvious sign.
13) Isolated non-syndromic genetic CBAVD. Not all patients have obvious cystic fibrosis symptoms or kidney abnormalities. Some have an isolated reproductive form caused by genetic changes that mainly affect the vas deferens.
14) SLC9A3-associated disease pathway. SLC9A3 has been reported in reviews and genetic discussions as a candidate or associated gene in some CBAVD cases, especially when CFTR testing is negative. The evidence is weaker than for CFTR and ADGRG2, but it is repeatedly discussed in the literature.
15) SCNN1B-associated pathway. SCNN1B is another gene that has been discussed as a possible associated contributor in some genetically unexplained cases. It is not as firmly established as CFTR, but it belongs to the group of reported candidate genes.
16) CA12-associated pathway. CA12 has also appeared in discussions of candidate genes in some men with congenital absence of the vas deferens. This should be understood as a reported association rather than a leading proven cause.
17) PANK2-associated pathway. PANK2 is another gene mentioned in some reports of possible association when the main genes are negative. Again, this is not a top proven cause, but it belongs to the growing group of candidate contributors.
18) Developmental defect with seminal vesicle agenesis or hypoplasia. In some men, CBAVD appears as part of a wider developmental problem of nearby reproductive structures, especially the seminal vesicles. This supports the idea of a broader embryologic tract defect.
19) Developmental defect associated with renal anomalies. Some cases occur with unilateral renal agenesis or other kidney anomalies, suggesting a developmental problem involving the closely linked urinary and reproductive systems. These cases may have a different genetic background from classic CFTR-related CBAVD.
20) Idiopathic or still unexplained genetic/developmental cause. A significant group of men with CBAVD still have no fully identified cause after current testing. This means science has not yet found every responsible gene or developmental pathway.
Symptoms
Many men with CBAVD have few or no day-to-day symptoms. The condition is often found only when a couple cannot achieve pregnancy. So some items below are true symptoms, while others are important clinical signs or common findings that patients notice during evaluation.
1) Infertility. This is the main symptom and the most common reason for diagnosis. The man usually cannot father a child naturally because sperm cannot move into the semen normally.
2) No sperm in semen. The semen may look normal to the eye, but laboratory testing shows azoospermia, meaning no sperm are present. This is a classic finding of obstructive infertility.
3) Low semen volume. Many affected men produce a smaller-than-expected amount of semen, often because the seminal vesicles may also be abnormal. This is an important clue during infertility workup.
4) Acidic semen pH. The semen can have a low pH, often below normal, which reflects absence or poor contribution from the seminal vesicles. This is not something the patient feels, but it is a key abnormality.
5) Low seminal fructose. Fructose is normally contributed by the seminal vesicles. When fructose is low or absent, doctors suspect a distal obstruction or absent seminal vesicles, which fits CBAVD.
6) Small or dry-feeling ejaculate. Some men describe the ejaculate as reduced, thin, or unusually small in amount. This is the patient-level experience behind the low-volume semen result.
7) Normal sexual desire but inability to conceive. A man may have normal libido and erections but still face infertility. This difference often causes confusion and delay in diagnosis.
8) No pain but repeated infertility failure. Many men feel completely healthy and have no scrotal pain, yet repeated attempts at conception do not succeed. The lack of pain can make the condition harder to suspect early.
9) Hidden reproductive tract abnormality found on exam. Some men do not notice any body change themselves, but the absent vas deferens is discovered when a doctor examines the scrotum. This is a common clinical presentation.
10) Mild chronic sinus problems in some cases. Men with CFTR-related CBAVD may also report chronic sinus congestion or sinus infections. This does not happen in every patient, but it supports a CFTR-related disorder.
11) Mild chest or breathing symptoms in some cases. Some patients have recurrent cough, chest infections, or other mild respiratory problems, especially when the condition lies on the cystic fibrosis spectrum.
12) Digestive symptoms in some patients. A minority may have mild digestive problems linked to CFTR dysfunction. These symptoms are not the main feature, but they can appear in atypical cystic fibrosis.
13) Anxiety after infertility testing. Emotional stress, worry, and sadness are common once the diagnosis is made. This is not a structural symptom of the vas deferens itself, but it is a very real patient experience.
14) Concern about passing a gene change to children. Many men feel distress after learning that CFTR or other gene variants can be inherited. This becomes especially important when assisted reproduction is being planned.
15) Discovery during partner infertility evaluation. Sometimes the “symptom” is simply that pregnancy does not occur, and the diagnosis appears only after the couple begins a full fertility assessment. This is one of the most typical real-world presentations.
Diagnostic tests
Doctors usually diagnose CBAVD by combining history, physical examination, semen testing, hormone testing, imaging, and genetic testing. No single test is enough in every patient. The goal is to confirm obstruction, show that the vas deferens are absent, look for related organ changes, and check for inherited risk.
1) Physical exam of the scrotum. The doctor gently feels the spermatic cord to see whether each vas deferens can be felt. In CBAVD, both vasa are usually absent on palpation.
2) Testicular size examination. The testes are often normal in size because sperm production can still be present. Normal-sized testes with azoospermia make obstructive causes more likely than primary testicular failure.
3) Epididymal examination. The epididymis may feel abnormal, full, or altered, depending on the anatomy. This helps the doctor understand whether the obstruction is congenital and how the tract developed.
4) General exam for CFTR-related features. Doctors may look for chronic sinus disease, lung issues, nutritional problems, or other clues suggesting atypical cystic fibrosis. This broad exam helps place CBAVD in the right disease spectrum.
5) Manual palpation of both vasa deferentia. This is a key bedside manual test. The doctor tries to trace the vas deferens on both sides; inability to feel them strongly supports the diagnosis.
6) Digital rectal examination when needed. In selected men, a rectal exam may help assess the prostate or suggest distal duct problems, especially in the wider workup of obstructive azoospermia. It is supportive, not specific by itself.
7) Semen analysis. This is one of the first and most important tests. It often shows azoospermia, meaning no sperm are found in the semen.
8) Repeat semen analysis. Doctors usually repeat the test because azoospermia should be confirmed and not assumed from one sample alone. Repetition improves diagnostic accuracy.
9) Semen volume measurement. Low ejaculate volume is common in CBAVD and is a major clue toward distal obstruction or seminal vesicle abnormality.
10) Semen pH testing. A low pH, often below normal, supports the diagnosis because seminal vesicle contribution is reduced or absent. This is a classic laboratory clue.
11) Seminal fructose test. Reduced or absent fructose suggests poor seminal vesicle secretion, which commonly accompanies CBAVD. This helps separate congenital obstruction from other infertility causes.
12) Hormone blood tests. Serum FSH, LH, and testosterone are often checked. In CBAVD they are commonly normal, which supports obstructive azoospermia rather than testicular failure.
13) CFTR genetic testing. Because CFTR is the leading cause, testing for CFTR variants is a central part of evaluation. This also helps with family planning and counseling.
14) ADGRG2 genetic testing. If CFTR testing is negative or incomplete, doctors may check ADGRG2, especially in strongly suggestive cases. This is useful because ADGRG2 is the second major gene linked to CBAVD.
15) Expanded genetic panel testing. In unresolved cases, broader panels may include candidate genes such as SLC9A3 and others. This is most useful when standard testing does not explain the condition.
16) Renal ultrasound. Kidney imaging is important because some men with CBAVD have renal agenesis or other urinary tract anomalies. A kidney scan should not be skipped.
17) Scrotal ultrasound. This test can help assess the epididymis, testes, and surrounding anatomy. It supports the diagnosis and may reveal associated abnormalities.
18) Transrectal ultrasound. This imaging test can evaluate the seminal vesicles, ejaculatory ducts, and nearby structures. It is useful when doctors want to define the lower reproductive tract anatomy more clearly.
19) MRI in selected cases. MRI is not always needed, but it can be used when anatomy is unclear or when ultrasound does not answer the main question. It gives a more detailed view of pelvic structures.
20) Sperm retrieval with pathological confirmation when planning fertility treatment. In some men, sperm are obtained from the epididymis or testis for assisted reproduction, and this can also help confirm that sperm production exists despite outflow obstruction. This is not the first test, but it becomes important for treatment planning.
Non-Pharmacological Treatments
The first treatment is specialist reproductive urology care. This means the patient is evaluated by a doctor trained in male infertility. The purpose is to confirm that the problem is truly CBAVD and not another cause of azoospermia. The mechanism is accurate diagnosis through history, physical examination, semen testing, hormone review, and imaging when needed, which prevents wrong treatment and guides the next steps safely. 3
The second treatment is genetic counseling. This is one of the most important parts of care. The purpose is to explain the role of CFTR and sometimes ADGRG2 mutations, and to discuss risks for children. The mechanism is education and risk calculation for the couple before sperm retrieval or IVF, which helps them make informed decisions about family planning. 4 6
The third treatment is CFTR mutation testing in the male partner. The purpose is to see whether CBAVD is part of a CFTR-related disorder. The mechanism is identifying gene changes that affect counseling, partner testing, and sometimes broader medical follow-up for cystic fibrosis features. 5 7
The fourth treatment is CFTR carrier testing in the female partner. The purpose is to estimate the chance that a future baby could have cystic fibrosis or a related disorder. The mechanism is combining both partners’ genetic results to guide IVF planning, preimplantation testing discussions, or natural conception counseling where relevant. 4 7
The fifth treatment is semen analysis and repeat confirmation. The purpose is to document azoospermia, semen volume, pH, and other clues that support obstruction. The mechanism is laboratory confirmation of the fertility pattern typical for CBAVD, which helps distinguish it from testicular failure. 3
The sixth treatment is physical examination of the scrotum and vas deferens. The purpose is to check whether the vas deferens can be felt and whether the testes appear otherwise normal. The mechanism is bedside identification of the absent duct, which often strongly points to CBAVD. 7 3
The seventh treatment is renal ultrasound when indicated. Some men with vas deferens abnormalities may also have kidney or urinary tract differences. The purpose is to look for associated structural findings. The mechanism is imaging-based screening that detects silent renal anomalies and improves full-body assessment. 6 4
The eighth treatment is transrectal or scrotal ultrasound when needed. The purpose is to study anatomy around the seminal vesicles, epididymis, and ejaculatory tract. The mechanism is visual confirmation of absent or abnormal reproductive ducts and exclusion of other blockages. 7 3
The ninth treatment is hormone testing such as FSH and testosterone in selected cases. The purpose is to confirm that sperm production may still be preserved and to rule out endocrine problems. The mechanism is identifying whether infertility is obstructive, hormonal, or mixed. 3
The tenth treatment is sperm retrieval planning. The purpose is to collect sperm directly from the epididymis or testis because sperm usually cannot reach the semen naturally. The mechanism is bypassing the missing vas deferens. This is one of the central evidence-based fertility treatments in CBAVD. 3 2
The eleventh treatment is sperm cryopreservation. The purpose is to freeze sperm once retrieved so repeated surgeries may be avoided. The mechanism is long-term storage of viable sperm for later ICSI use. 4 2
The twelfth treatment is IVF with ICSI. This is the main fertility-building therapy for many couples with CBAVD. The purpose is pregnancy using retrieved sperm. The mechanism is injecting a single sperm directly into an egg, which bypasses the need for a vas deferens. 3 8
The thirteenth treatment is preimplantation genetic testing discussion. The purpose is to reduce the chance of transferring embryos affected by serious inherited disease in selected couples. The mechanism is embryo testing after IVF when both parents’ genetics suggest a meaningful risk. 7 4
The fourteenth treatment is psychological counseling. Infertility can bring sadness, shame, fear, and relationship strain. The purpose is mental support. The mechanism is lowering stress, improving communication, and helping couples continue complex fertility care. 8 3
The fifteenth treatment is couple fertility counseling. The purpose is to align timing, finances, expectations, and partner evaluation. The mechanism is coordinated care for both partners, which improves decision-making and reduces delays. 8
The sixteenth treatment is healthy weight control. The purpose is to support general reproductive health and surgical readiness. The mechanism is lowering inflammation and metabolic stress, which may help overall semen and treatment outcomes even though it does not regrow the absent ducts. 9 10
The seventeenth treatment is smoking cessation. The purpose is to protect sperm quality and general health. The mechanism is reducing oxidative stress and DNA damage in sperm retrieved for ART. 10 3
The eighteenth treatment is limiting alcohol and recreational drugs. The purpose is to support safer fertility treatment and better sperm quality. The mechanism is lowering toxic effects on spermatogenesis and endocrine balance. 9 10
The nineteenth treatment is heat avoidance such as hot tubs and high heat exposure. The purpose is to protect testicular function before sperm retrieval. The mechanism is preventing heat-related harm to sperm production. 3
The twentieth treatment is regular follow-up in a CF or infertility clinic when CFTR-related disease is present. The purpose is full-body care, not just fertility care. The mechanism is ongoing review of lung, nutrition, liver, and reproductive health in men whose CBAVD is part of a wider CFTR disorder. 2 11
Drug Treatments
There is no FDA-approved drug that can create a missing vas deferens. Drug treatment is mainly useful when CBAVD happens with cystic fibrosis or another CFTR-related disease, or when medicines are used around fertility procedures. The most evidence-based FDA-approved drugs in this setting are CFTR modulators. 3 2
Ivacaftor is a CFTR potentiator used only for specific responsive CFTR mutations. A common adult dose is 150 mg by mouth every 12 hours with fat-containing food. Its purpose is to improve CFTR channel function in eligible patients with cystic fibrosis, not to regrow the vas deferens. The mechanism is increasing opening of the abnormal CFTR channel. Important side effects include liver enzyme elevation, headache, stomach symptoms, and cataract warning in children. 12
Lumacaftor/ivacaftor is a combination used in patients with cystic fibrosis who are homozygous for the F508del mutation. A common adult dose is two tablets every 12 hours with fat-containing food. The purpose is to improve CFTR protein processing and channel activity in eligible CF, not to reverse CBAVD anatomy. Side effects include breathing symptoms, liver test changes, nausea, and drug interactions. 13
Tezacaftor/ivacaftor is another modulator combination for selected genotypes. A common adult schedule is one tezacaftor/ivacaftor tablet in the morning and one ivacaftor tablet in the evening, taken with fat-containing food. Its purpose is better CFTR trafficking and function in eligible CF patients. Side effects include headache, sinus symptoms, nausea, and liver enzyme elevation. 14
Elexacaftor/tezacaftor/ivacaftor plus evening ivacaftor is widely used in eligible patients with at least one F508del mutation. A common adult dose is two combination tablets in the morning and one ivacaftor tablet in the evening with fat-containing food. Its purpose is strong CFTR rescue in eligible CF. Side effects include rash, headache, gastrointestinal symptoms, liver injury risk, and many drug interactions. 15
Vanzacaftor/tezacaftor/deutivacaftor is a newer once-daily CFTR modulator combination approved for selected cystic fibrosis patients with responsive mutations. Its purpose is to improve CFTR protein correction and function in systemic CF care. It does not restore absent vas deferens. Liver monitoring and interaction review are important. 16
For men with CBAVD who undergo fertility procedures, doctors may use procedure-related medicines such as antibiotics, local anesthetics, sedation drugs, or pain medicines, but these are not disease-specific CBAVD cures. Their purpose is infection prevention, comfort, and safe sperm retrieval or IVF procedures. The exact drug, dose, and timing vary by clinic, surgery type, allergy history, and liver or kidney status. 3
Because the evidence does not support 20 FDA-approved drugs specifically for CBAVD itself, the honest evidence-based conclusion is that medicines have a supportive role, while the main fertility treatment remains sperm retrieval plus ART, and the main medical treatment is management of associated cystic fibrosis when present. 2 3
Dietary Molecular Supplements
Evidence for supplements in CBAVD is weaker than for surgery and ART. Supplements may support general sperm health or nutrition, but they do not rebuild the missing vas deferens. They should be used only after discussion with a doctor, especially if IVF is planned. 10 17
Zinc may support normal sperm development and antioxidant defense. Typical doses in supplements are often 15 to 30 mg daily. Its function is support of enzyme activity and reproductive tissue health. Too much can cause stomach upset and copper deficiency. 17
Selenium is an antioxidant trace mineral. Common supplemental doses are around 100 to 200 mcg daily. Its function is protection of sperm cell membranes from oxidative damage. Excess selenium can be toxic, so higher doses should not be used casually. 17
Coenzyme Q10 is used by some fertility specialists for energy support in sperm cells. Common doses are 100 to 300 mg daily. Its mechanism is mitochondrial support and antioxidant activity. Evidence is mixed but biologically reasonable. 17
L-carnitine is sometimes used to support sperm motility and energy metabolism. Common doses are 1 to 3 grams daily. Its mechanism is transport of fatty acids into mitochondria for energy production. 17
Vitamin C may help reduce oxidative stress. Common doses are 250 to 1000 mg daily. Its mechanism is free-radical neutralization. High doses may upset the stomach in some people. 17
Vitamin E is another antioxidant used in male fertility support. Common doses are 200 to 400 IU daily. Its mechanism is protection of cell membranes from oxidative damage. It can interact with blood thinners. 17
Folate supports DNA synthesis. Common doses are 400 to 800 mcg daily. The mechanism is support of healthy cell division. It is often paired with zinc in fertility supplements. 17
Omega-3 fatty acids may help cell membrane function and inflammation control. Common doses are 1 to 2 grams daily of combined EPA and DHA. The mechanism is membrane fluidity and anti-inflammatory signaling. 17
Vitamin D is used when deficiency is present. Common doses vary, often 1000 to 2000 IU daily, but blood-test-guided dosing is better. The mechanism is broad endocrine and immune support. 17
Pancreatic enzyme and CF vitamin support may be needed in men whose CBAVD is part of cystic fibrosis with malabsorption. These do not treat infertility directly, but they support nutrition, weight, and general health. Dosing is individualized in CF care. 11 18
Immunity Booster, Regenerative, or Stem-Cell Drug Options
At present, there are no established stem-cell drugs or regenerative medicines approved to regrow the vas deferens in CBAVD. That is the key evidence-based message. 4 3
If the patient has cystic fibrosis, the most relevant “regenerative-like” medicines are still the CFTR modulators already listed, because they partially correct the underlying protein problem in eligible genotypes. They improve systemic disease control but do not reverse the congenital absence of the ducts. 12 15
So the honest list in this section is simple: no proven immune booster drug, no approved stem-cell drug, no approved vas deferens regenerative drug, no gene-therapy cure for CBAVD in routine care, no fertility pill that reopens the absent ducts, and no injectable medicine that replaces sperm retrieval plus ART. 3 4
Surgeries or Procedures
PESA means percutaneous epididymal sperm aspiration. A needle is used to collect sperm from the epididymis. It is done because sperm are present upstream even though the vas deferens is missing. 4 3
MESA means microsurgical epididymal sperm aspiration. It is a more controlled microsurgical sperm retrieval method. It may provide good sperm yield for freezing and later ICSI. 4
TESA means testicular sperm aspiration. A needle is used to collect sperm directly from the testis. It is done when epididymal retrieval is not suitable or does not give enough sperm. 3
TESE means testicular sperm extraction. A small piece of testicular tissue is removed to find sperm. It is done to support IVF with ICSI. 4 8
IVF with ICSI embryo procedure is not surgery on the vas deferens, but it is the main reproductive procedure that helps a couple achieve pregnancy after sperm retrieval. It is done because the sperm cannot enter semen naturally. 3 8
Prevention Points
CBAVD itself is congenital, so it usually cannot be prevented after conception. Prevention mainly means prevention of surprises, complications, and inherited risk through early evaluation. 1 6
The best prevention steps are early infertility evaluation, CFTR testing, partner carrier testing, genetic counseling, avoiding smoking, limiting alcohol and drugs, keeping healthy weight, avoiding excess heat, protecting general CF health if present, and freezing sperm when retrieved so repeat procedures may be avoided. 3 10
When to See a Doctor
See a doctor if a couple has tried for pregnancy for 12 months without success, or sooner if the man has very low semen volume, known cystic fibrosis, family history of CFTR disease, absent vas deferens on exam, or prior infertility testing suggesting azoospermia. Also seek care for chronic cough, recurrent chest infections, digestive problems, or poor weight gain, because these may suggest broader CFTR-related disease. 2 3
What to Eat and What to Avoid
Helpful choices include a Mediterranean-style eating pattern with fruits, vegetables, legumes, fish, nuts, olive oil, whole grains, and balanced protein. Good hydration, healthy weight, and correction of vitamin or mineral deficiencies are also useful. If cystic fibrosis is present, nutrition may need more calories, enzyme support, and vitamin monitoring under a CF team. 19 11
Try to limit smoking, heavy alcohol, recreational drugs, ultra-processed foods, trans fats, repeated high heat exposure, and extreme bodybuilding supplement use without medical advice. These choices do not cause the missing ducts, but they may worsen general reproductive health and procedure readiness. 10 17
FAQs
Is CBAVD the same as low sperm count? No. Many men with CBAVD make sperm normally, but sperm cannot get into the semen. 1
Can natural pregnancy happen? Usually not, because the sperm transport tubes are absent. 2
Can a pill cure it? No pill can regrow the missing vas deferens. 3
Can men with CBAVD still have biological children? Yes, many can through sperm retrieval and IVF with ICSI. 8
Is sexual function normal? Usually yes. Libido and erections are often normal. 1
Is CBAVD linked to cystic fibrosis? Very often, yes, through CFTR gene changes. 5
Should my partner get tested? Yes, partner carrier testing is strongly important. 7
Do all men with CBAVD have lung disease? No. Some have only infertility, while others have broader CFTR-related disease. 5
Will surgery rebuild the vas deferens? Usually no. Treatment focuses on retrieving sperm and bypassing the missing tubes. 4
Is sperm production always normal? Often normal, but not always; full evaluation still matters. 4
Are supplements enough? No. Supplements may support general health but do not fix the structural defect. 17
Can this be inherited? Yes, especially when related to CFTR or ADGRG2 variants. 6
Should kidney imaging be done? It may be advised in selected men because some duct anomalies are linked with renal anomalies. 6
Is stem-cell treatment available? Not as a proven routine treatment for CBAVD. 3
What is the best treatment overall? The best evidence-based path is expert evaluation, genetic counseling, sperm retrieval, and IVF with ICSI when pregnancy is desired. 3 8
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: March 10, 2025.
